Smaller total brain volumes in male HD mutation carriers suggests brain development may be different in HD.
Genetic evidence suggests connections between a polyQ disease and ALS (Lou Gehrig’s disease). Why should HD people ca
New data suggest there may be twice as many people with HD symptoms as previously thought – and even more at risk
Merger of two major Huntington’s Disease observational trials creates ENROLL-HD
Two clinical trials in Europe and the USA have suggested a new drug, Huntexil, might improve movements in HD. The nex
DOMINO clinical trial result: minocycline doesn’t slow down HD and shouldn’t be studied in larger trials.
The one-year report from the TRACK-HD study demonstrates a number of changes in pre-symptomatic HD-mutation carriers